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Nessuno deve credere di essere solo, perché in ciascuno vive il sangue di coloro che l'hanno generato, ed 
è una cosa che va indietro fino alla notte dei tempi. Così siamo solo la curva di un fiume, che viene da 
lontano e non si fermerà dopo di noi. 
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 RIASSUNTO 
Nelle cellule di paratiroide è espresso il recettore mineralcorticoide Inoltre, 
nell’iperaldosteronismo primario i livelli sierici di ormone paratiroideo (PTH) sono 
aumentati.  Questi dati unitamente al fatto che il PTH stimola la secrezione di 
aldosterone suggeriscono una relazione tra paratiroidi e zona glomerulosa del surrene. 
L'analisi di tale relazione è stata ostacolata finora dalla mancata disponibilità di una linea 
cellulare di paratiroide idonea per gli studi in vitro. 
Obiettivo. Investigare la posibilita di sviluppare una linea cellulare di paratiroide umana 
che permetta di investigare se, e attraverso quali meccanismi, la secrezione di PTH sia 
regolata dall’aldosterone. 
Risultati. Dopo digestione di tessuto ottenuto da adenomi di paratiroide sono state 
isolate le cellule utilizzando due metodi: 1) immunoseparazione mediante biglie 
incubate con CD90, anticorpo di membrana specifico per i fibroblasti, 2) separazione 
mediante filtrazione.  L’espressione di marcatori propri delle cellule di paratiroide è stata 
confermata tramite real time qRT-PCR, microscopia elettronica e immunocitochimica 
nelle cellule in coltura fino al decimo giorno.  
Su la base del grado di immunostaining  per il PTH e all'intensità di segnale dopo 
caricamento delle cellule con tetramethylrhodamine-metil-estere (TMRM), una sonda 
specifica per misurare il potenziale di membrana dei mitocondri.,due fenotipi cellulari 
sono stati identificati.  
Conclusioni. Con il protocollo messo a punto nel nostro laboratorio per isolare e 
coltivare cellule di paratiroide umana si è potuto accertare che le cellule della coltura 
primaria mantengono il loro fenotipo, caratterizzato dall'espressione dei marcatori 
propri delle cellule di paratiroide,  fino al decimo giorno. Un processo di filtrazione, 
seguito dall'espressione dei marcatori cellulari e dall’analisi della captazione di TMRM 
mitocondriale consentono la separazione e l'identificazione delle due sottopopolazioni 
di cellule che formano il tessuto paratiroideo, cellule ossifile e cellule principali. 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abstract 
 
ABSTRACT 
Background. The detection of the mineralocorticoid receptor in parathyroid cells 
alongside recent evidences implicating the parathyroid hormone (PTH) in 
overproduction of aldosterone in primary aldosteronism in spite of suppression of the 
renin-angiotensin system indicate a relationship between parathyroids and the 
adrenocortical zona glomerulosa.  The investigation of this relationship has been 
hampered due to lack of parathyroid cell line suitable for in vitro studies.  
Objective. To develop a technique to obtain a primary culture of human parathyroid 
cells with high yield and purity and to obtain subpopulations of chief and oxyphil cells 
Results. After digestion of tissue from parathyroid adenomas, we isolated cells using an 
immunomagnetic bead method to remove fibroblasts and filtration devices to isolate 
cells by size. real-time qPCR evidenced expression of specific markers of parathyroid 
cells in cultured cells until day 10. At protein level, we found that some cells showed 
marked PTH immunostaining, whereas the remaining cells showed only a faint signal, 
suggesting the presence of two cell types. After loading cells with 
tetramethylrhodamine-methyl-ester (TMRM), we found two cell types, which differed 
for the fluorescent signal intensity.  
Conclusions. We found an optimal protocol to obtain a culture of human parathyroid 
cells that includes immunobinding-based technique and cellular filtration. Cultured cells 
retain their characteristic expression profile until day 10. Analysis of the mitochondrial 
uptake of TMRM and cell markers allows identification of two cell types forming the 
parathyroid tissue, i.e. oxyphil and chief cells. 
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INTRODUCTION 
1. PARATHYROID GLANDS  
The parathyroids are four small glands located in humans in the cervical region, with one 
gland behind each of the upper and each of the lower poles of the thyroid.  Its main 
function is the secretion of parathyroid hormone (PTH), a hormone that is essential for 
the regulation of calcium and phosphate metabolism.  Each parathyroid gland is about 6 
millimeters long, 3 millimeters wide, and 2 millimeters thick, with an appearance of dark 
brown fat that renders the glands similar to a lobule of the thyroid gland. For this 
reason, before the importance of these glands was generally recognized, total or 
subtotal thyroidectomy frequently resulted in the removal of the parathyroid glands 
with ensuing hypoparathyroidism.  Removal of half parathyroid glands usually causes no 
major physiologic abnormalities, removal of three glands causes only transient 
hypoparathyroidism and even a small amount of parathyroid tissue is  sufficient to 
provide enough function to avoid hypoparathyroidism showing the ability of the gland to 
increase in dimensions and function (1).  
The parathyroid gland of the adult contains mainly chief cells, with a small to moderate 
number of oxyphil cells, but these are absent in young humans and some animals.  The 
chief cells are believed to secrete most, if not all, PTH.  However, the oxyphil cells, which 
are deemed to be modified or depleted chief cells that no longer secrete hormone, may 
acquire the ability to produce PTH with aging or upon exposure functional stress (1, 2). 
Histologically, oxyphil cells are larger than chief cells (12–20 µm vs.6–8µm), with more 
eosinophilic cytoplasm due to high mitochondrial content. The detection of transitional 
oxyphil cells, which are more eosinophilic but similar in size to the chief cells, suggests 
that oxyphil cells derive from chief cells.  Additional evidence for a chief cell-to-oxyphil 
cell transdifferentiation is that both transitional and oxyphil cells express PTH and Glial 
Cell Missing 2 (GCM2), a parathyroid-specific transcription factor that is essential for 
parathyroid gland development (2). 
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1.1 Function 
A remarkable feature of the parathyroid glands is sensitivity to small changes in serum 
concentration of calcium ion (Ca2+), which leads to large changes in PTH secretion.  This 
feature is unique to the parathyroid glands.  All other endocrine glands, in fact, increase 
hormone secretion after exposure to high extracellular Ca2+ concentrations.   
Although the four parathyroid glands are quite small, they are very vascular. As the 
blood filters through the parathyroid glands, they detect the amount of calcium present 
in the blood and react by increasing or decreasing  PTH synthesis.  When the calcium 
level in the blood is too low, the cells of the parathyroid glands sense it and produce 
PTH. Once the PTH is released into the blood, it circulates to act in a number of target 
tissues to increase the amount of calcium in the blood. When the calcium level in the 
blood is too high, parathyroid cells produce less PTH, allowing calcium levels to 
decrease. This feed-back mechanism acts constantly, thereby maintaining Ca2+  (and 
PTH) in a very narrow "normal" range (1). 
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 2. Parathyroid Cell Markers 
2.1 Parathyroid Hormone (PTH) 
PTH is synthesized on the ribosomes in the form of a preprohormone, a polypeptide 
chain of 110 amino acids that is cleaved first to a pro-hormone with 90 amino acids and 
then to the mature hormone itself comprising 84 amino acids at the endoplasmic 
reticulum and Golgi apparatus.  The final hormone PTH, which finally is packaged in 
secretory granules in the cytoplasm of the cells, has a molecular weight of about 9,5 
KDa. Smaller compounds with as few as 34 amino acids adjacent to the N terminus of 
the molecule were also isolated from the parathyroid glands, which are functionally 
active.  Because the kidneys rapidly remove the whole 84-amino acid hormone within 
minutes, but fail to remove many of the fragments for hours, a large share of the 
hormonal activity can be caused by the fragments (3). 
The overall role of PTH is to increase Ca2+ concentration via three different mechanisms 
(1): 
1. PTH has two main effects on bone in causing absorption of Ca2+ and phosphate.  
One is the rapid phase that begins within minutes and increases progressively for 
several hours. This phase results from activation of the bone cells (mainly the 
osteocytes) to promote Ca2+ and phosphate reabsorption.  The second phase is  
much slower one, requiring several days or even weeks to become fully 
developed.This is because it results from proliferation of the osteoclasts, 
followed by increased osteoclastic reabsorption of the bone itself, not merely 
absorption of the Ca2+ phosphate salts from the bone. 
2. PTH increases renal tubular reabsorption of Ca2+ while diminishing phosphate 
(PO4) reabsorption.  Moreover, it increases the rate of reabsorption of Mg+ and 
H- ions while it bennts the reabsorption of Na, K+, and amino acid as it does for 
PO4.  The increased Ca2+ absorption occurs mainly in the late distal 
tubules, the collecting tubules, the early collecting ducts, and to a lesser extent 
the ascending loop of Henle. Such effect is the most relevant. Actually, were it 
not for the PTH- withdrawal in the kidneys to increase Ca2+ reabsorption, a 
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continual loss of Ca2+ into the urine would eventually deplete both the 
extracellular fluid and the bones of this mineral. 
3. PTH greatly enhances both Ca2+ and PO4 reabsorption from gut by increasing 
the formation in the kidneys of 1, 25-dihydroxycholecalciferol (1,25(OH)2D) from 
25-hydroxycholecalciferol (abbreviated 25(OH)D) (Fig.1). 
Figura 1: Overview of the PTH Effects  Decrements in serum calcium levels stimulate PTH secretion 
by the parathyroid glands(Initial stimulus), which targets the kidney to reduce urinary Ca
2+
 
excretion and enhance the excretion of phosphate (PO4), and targets bone to increase the efflux of 
Ca
2+
 and PO4 (Physiological response). The resulting increase in 1,25(OH)2D targets the 
gastrointestinal tract to increase dietary absorption of calcium.The final result is an increase in the 
amount of Ca
2+
 in the blood. 
Adapted from ©2013 Pearson Education, Inc  
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2.2 Calcium Sensing Receptor (CaSR) 
The ability of chief cells of the parathyroid glands to sense small changes in blood 
ionized Ca2+ levels and trigger the adaptive responses is mediated by the calcium sensing 
receptor (CaSR), which is located on the cell surface. 
The CaSR was the first receptor to be described for which the natural ligand is an ion. It 
is a member of subfamily C of G protein-coupled receptors (GPCRs), with a large 
extracellular domain, seven membrane-spanning regions and an intracellular portion 
that couples to G proteins and other signal transduction pathways. The gene encoding 
the protein in humans is located on chromosome 3q13.3-21 (4).   
The protein CaSR is a member of the C family of G-protein–coupled receptors and, in 
humans, is 1,078 amino acids in length. The amino-terminal portion of the molecule 
contains approximately 600 aminoacid residues and forms a very large extracellular 
domain (5, 6). Clusters of acidic amino acids in this portion of the CaSR are thought to 
interact with extracellular Ca2+ ions, thereby modulating the levels of receptor activation 
and signal transduction (7-9). Although calcium ions represent the physiologically 
relevant ligand for the CaSR in vivo, a number of divalent, trivalent, and polyvalent 
cations, and various amino acids, also can activate the CaSR in vitro (5). 
Decreased expression of both CaSR and vitamin D receptor (VDR) expression has been 
described in parathyroid adenomas and hyperplastic parathyroid tissues (10-13). It is 
unknown whether such changes are correlated, but alterations in CaSR expression may 
contribute to abnormalities in cell cycle and cell growth in the parathyroid tissue.  In vivo 
findings suggest that signaling through the CaSR is largely preserved in primary 
hyperparathyroidism even modest reductions in CaSR expression (4). Despite to these 
findings, it is not entirely clear if the reductions in protein expression alone are sufficient 
to attenuate signal transduction by CaSR in hyperplastic or adenoma parathyroid tissue 
or whether such changes explain defects in calcium sensing and their impact in clinical 
conditions. 
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2.3 Glial Cells Missing 2 (GCM2) 
The thymus, thyroid, and parathyroid glands develop from the pharyngeal region in 
vertebrates, with contributions both from pharyngeal endoderm and from neural crest 
cells in the pharyngeal arches.  Studies of gene knockout mice showed that the hoxa3, 
pax 1, pax 9, and Eya1 transcription factors are needed to form parathyroid glands as 
well as many other pharyngeal pouch derivatives, such as the thymus (14).  Gunther et 
al. studied GCM2, a mouse homologue of Drosophila GCM, a transcription factor whose 
expression is restricted to the parathyroid glands, and showed that GCM2-deficient mice 
lacked parathyroid glands and exhibited hyperparathyroidism, thereby identifying GCM2 
as a master regulatory gene of parathyroid gland development. In contrast, thymus 
development was not affected by GCM2 deletion.  Despite the lack of parathyroid 
glands, GCM2-deficient mice had PTH serum levels similar to those of wild-type mice (in 
the presence of hypocalcemia), as did parathyroidectomized wild-type mice.  Expression 
and ablation studies identified the thymus, where GCM1, another GCM homologue, is 
expressed as the additional, downregulatable source of PTH. Thus, GCM2 deletion 
uncovered an auxiliary mechanism for the regulation of calcium homeostasis in the 
absence of parathyroid glands.  A patient with a defective GCM B gene, the human 
equivalent of GCM-2, exhibited hypoparathyroidism and complete absence of PTH from 
the bloodstream (15, 16). 
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2.4 Chromogranin-A 
The chromogranins (Chromogranin-A and Chromogranin-B), secretogranins (type 
I and II) and additional related proteins (7B2,NESP55, proSAAs, and VGF) that together 
comprise the Granin Family, play essential roles in regulating the secretory pathway that 
are responsible for controlled delivery of peptides, hormones neurotransmitters and 
growth factors (17).  
Granins are relatively abundant acidic proteins that localize in secretory vesicles, where 
they bind Ca2+ and form aggregates.  Endocrine, neuroendocrine, and neuronal cells 
secrete a variety of peptides and hormones via Ca2+dependent release.  The number of 
dense core secretory granules in an endocrine cell (~10, 000) together with the high Ca2+ 
binding capacity of resident granin proteins and their abundance (~2-4mM), constitute a 
major intracellular calcium reservoir (18,19). 
Chromogranin-A (CGA), also referred to as secretory protein-I, is a 50-kDa protein 
synthesized and secreted by most endocrine cells together with the native hormone 
(20). It appears to be the major secretory protein in the parathyroid secretory granules 
(21) and, therefore, can be considered a marker of parathyroid adenoma (22). 
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2.5 Localization of the Markers in the Parathyroid Gland 
 
Immunohistologic studies performed in the parathyroid glands of chronic kidney disease 
(CKD) patients  showed higher expression of CaSR and PTH in oxyphil cells,  whereas 
both oxyphil  and chief cells express the transcription factor, GCM2 (1) which is critical 
for the parathyroid development and expression of PTH and CaSR (23). GCM2 was 
heterogeneously expressed, with the highest expression in the oxyphil clusters and the 
lowest in the chief cell nodules, suggesting it may be responsible, in part, for the higher 
expression of PTH. PTH was modestly, although significantly, higher in oxyphil clusters 
than the diffuse chief cells while CaSR expression was slightly, but significantly, higher in 
oxyphil clusters and nodules than in chief cells, whereas the VDR was not differentially 
expressed (Table 1). The authors concluded that oxyphil cells from CKD patients express 
parathyroid markers found in chief cells, strongly suggesting that oxyphil cells are not 
simply deactivated chief cells. The presence of VDR and CaSR suggest that oxyphil cells 
release PTH in a regulated fashion and this fact could be relevant in the interconnection 
of parathyroid glands with others tissues (1). 
 
 
 
Table 1: Cellular Characteristic of Parathyroid Tissue 
 
Characteristics Chief cells Oxyphil cells 
Size  6 -8 μm 12 -20 μm 
Cytoplasm Eosinophilic cytoplasm Cytoplasm more eosinophilic 
(mitochondrial content) 
Parathyroid 
markers  
PTH           + 
GCM2      + 
CaSR        + 
VDR          + 
PTH         + 
GCM2    + 
CaSR       ? 
VDR         ? 
 
 
 
 
Adapted from Ritter S. Cynthia et al. Differential Gene Expression by Oxyphil and Chief Cells of Human 
Parathyroid Gland. J Clin Endocrinol Metab 2012. 97(8). (+) Positive  protein expression , (?) Variable 
protein expression. 
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3. PARATHYROID HORMONE AND ALDOSTERONE: A LINK 
BETWEEN SYSTEMS. 
Experimental data published by Martin, et al. in early 70s provided the evidence of 
an interaction between the adrenal and parathyroid glands.  The Authors investigated 
electrolyte excretion  in rats adrenalectomy (ADX), parathyroidectomy (PTX) or both 
(ADX-PTX) before and during administration of aldosterone, parathyroid extracts, or 
both hormones.  Increased urine Na+ and CI- and decreased K+ were found in the ADX-
PTX rats compared to the other groups.  Aldosterone caused a decrease in all groups in 
urine Na+, CI-  and PO4, except, and in stool Ca
2+ in ADX-PTX rats, along a rise in urine K+.  
Parathyroid extracts, in contrast, caused an increase in urine Na+ and CI-  in all groups 
except the ADX-PTX rats, and in urine and stool PO4 and Ca
2+ in all groups.  The 
administration of the both hormones caused a similar decrease in urine Na+ but much 
higher urine K+  and CI-  than with aldosterone alone.  Phosphaturic effect parathyroid 
extracts was blocked by addition of aldosterone, but little effect was found on stool PO4 
and urine and stool Ca2+.  Addition of aldosterone reversed these effects, which 
appeared related to presence or absence of parathyroid glands.  This study suggested a 
complex interrelation between adrenal and parathyroid glands that involve electrolyte 
excretion (24), can be considered the seminal study that 'inspired' all subsequent and 
more indeeping studies. 
Later, many data suggested that deregulation of aldosterone or PTH can play an 
important role in the development and progression of cardiovascular disease.  However, 
the mechanisms underlying the interactions between aldosterone and PTH remained 
unknown (25). 
Our group recently demonstrated the presence of Mineralocorticoid Receptor (MR) in 
parathyroid-secreting cells in the PTH-secreting adenoma and in the normal parathyroid 
gland (Fig. 2); another hallmark result was the expression of PTH receptors in the 
aldosterone-producing adenoma (APA) tissue and in surrounding satellite nodules of the 
tumor (26). The activated MR–aldosterone complex regulates transcription of numerous 
genes in a tissue-specific pattern. Experimental and clinical studies documented that 
aldosterone mediated inflammatory and fibrotic effects were associated with left 
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ventricular hypertrophy and reduced kidney function (27). Tomaschitz and others 
recently reported an independent association between plasma aldosterone levels within 
the ‘normal range’ and cardiovascular mortality, in particular fatal stroke and sudden 
cardiac death (28-30). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figura 2:  A‑B. Representative sections of human parathyroid gland incubated with a specific antibody 
against the human mineralocorticoid receptor (MR) showing intense nuclear staining and a weaker 
cytoplasm staining. C. A section of normal human kidney was similarly exposed to the same antibody 
as a positive control shows a strong cytoplasmic expression in the tubules and the lack of staining in 
glomeruli.. D. Agarose gel electrophoresis of MR gene amplicon from the parathyroid adenoma of 
index case (lane 2) and a normal human parathyroid (lane 3) shows the transcript of this gene in these 
tissues. Untranscribed RNA from normal human parathyroid (lane 4) and water served as negative 
controls (lane 5).  
Adapted from Maniero C et al Hypertension 2011;58:341-346. 
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The identification of PTH receptors within the cardiovascular system (cardiomyocytes, 
vascular smooth muscle, and endothelial cells) indicates that inappropriate PTH 
secretion may impact on the  cardiovascular (CV) health. Administration of PTH after 
myocardial infarction attenuates ischemic cardiomyopathy by increasing migration of 
bone marrow-derived stem cells to the ischemic myocardium (31). On the other hand 
the PTH excess in primary hyperparathyroidism (PHPT) is linked in the long-term to 
adverse effects as bone loss and increased fracture risk, coronary microvascular 
dysfunction, derangement of lipid and glucose metabolism, subclinical aortic valve 
calcification, increased aortic stiffness, endothelial dysfunction and arterial hypertension 
(32–38). Accordingly, patients with PHPT have a remarkably higher risk to die from CV 
causes compared with the general population (39, 40). Various observational linked 
higher levels of PTH even in the absence of PHPT to an increased risk of CV morbidity 
and mortality (41–47). Elevated PTH levels in patients with a declining kidney function 
have been related to soft tissue calcifications and subsequent adverse cardiovascular 
diseases (CVD) outcome (48, 49). Figure 3 shows a schematic representation of the 
interplay between PTH and aldosterone hormone.  
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Figura 3:  Overview of the mechanisms and cardiovascular impact resulting from the interaction of aldosterone and 
parathyroid hormone. Inappropriately elevated aldosterone (ALD) secretion results in accelerated renal (and fecal) 
calcium and magnesium loss and salt/water retention and increased parathyroid hormone (PTH) secretion via activating 
PTHR and MR. Dietary salt loading pronounces aldosterone related renal cation loss. MR-mediated hypocalcemia 
(hypomagnesemia) further stimulates PTH secretion (via activating the calcium sensing receptor (CaSR). PTH induces 
myocardial damage via stimulating calcium influx in cardiomyocytes resulting in an intracellular and mitochondrial 
calcium overload and reduction in intra-mitochondrial ATP levels contributing to a disturbed redox status and increased 
oxidative stress. Aldosterone excess exerts genomic and non-genomic profibrotic and proinflammatory effects on blood 
vessels and the myocardium. Adapted from Tomaschitz A, et al. Metabolism 2014;63(1):20-31.. 
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3.1 The Role of PTH in Primary Aldosteronism 
 
Primary aldosteronism (PA), is characterized by chronic elevation in plasma aldosterone, 
is the most common endocrine cause of secondary arterial hypertension (50).  The term 
‘primary’ implies that the underlying mechanisms are currently unknown. The 
prevalence of PA was found to be 11.2% in the hypertensive patients referred to a 
specialized center for high blood pressure and can be estimated to be 17–23% in drug-
resistant hypertension.  Several large cross-sectional and prospective studies showed a 
relationship between circulating aldosterone levels and mortality risk (26,50–57), 
thereby providing evidence that aldosterone causes organ damage and enhances the 
cardiovascular risk. Absolute aldosterone excess is in fact strongly associated with a 
higher risk of development and progression of left ventricular hypertrophy, coronary 
artery disease, sudden cardiac death, chronic kidney disease and stroke (57-59). 
The classical view that aldosterone acts exclusively on the electrolyte transport in 
epithelial cells has been broadened after the MR has been identified in non-epithelial 
cells, thereby providing experimental support to the aforementioned studies (26, 50–
57).Moreover, in addition to the classical genomic effects, non-genomic aldosterone-
mediated effects have been identified in various tissues outside of the kidneys and 
colon, e.g. endothelial cells and cardiomyocytes (60,61), further supporting a role of 
aldosterone in mediating organ damage.  However, novel mechanisms are emerging. 
Recent evidences, actually, strongly suggest that PTH may sustain or trigger the excess 
production of aldosterone in PA despite the suppression of the renin-angiotensin 
system, the high blood pressure and hypokalaemia, all factors that would be expected to 
shut off aldosterone secretion (61, 62). One study performed by our group showed that 
patients with PA had  significantly higher plasma PTH than patients with primary 
(essential) hypertension, even being characterized by comparable urinary Ca2+ excretion 
and similar deficient 25(OH) vitamin D.  Of great interest, adrenalectomy normalized 
PTH levels and increased ionized Ca2+  in APA patients (63) (Fig.4). 
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In another study from Italy it was observed that the significantly high serum 
concentrations of intact PTH found in 120 PA patients decreased after 1 month of MR 
blockade with 100 mg spironolactone daily, along an increase in serum-ionized calcium 
(64), thus further supporting the contention that PTH plays a role in PA.  
 
 
 
Data from our laboratory are consistent with those from other groups.  Pilz et al., by 
comparing the effects of MR blockade and adrenalectomy on PTH levels in patients with 
PA. All studies found PTH levels were significantly higher in PA patients compared with 
those of essential hypertension patients and adrenal surgery or treatment with MR 
antagonist, were associated with a reduction of PTH and arterial blood pressure at 
follow-up (30). 
 
 
 
The higher plasma PTH levels found in PA patients than in essential hypertension could 
also have a clinical impact: A study  from our laboratory showed that PTH levels are 
elevated in PA patients with an APA and much less as in those with bilateral adrenal 
hyperplasia (BAH).  Hence, it was proposed that raised serum PTH levels can be useful 
for selecting the PA patients to be submitted to adrenal vein sampling (AVS) and for 
discriminating between subtypes of PA (65).  
Finally, given the emerging evidence implicating hyperparathyroidism as a 
cardiovascular risk factor, it could be arguable that the high serum PTH found in PA 
patients contributes to the excess cardiovascular damage (Fig. 5) (26). 
 
 
 
Figure 4. The bar graphs show various indexes of 
Ca2
+ 
metabolism in patients with primary 
aldosteronism due to an APA and in matched 
patients with primary (essential) hypertension 
(PH). Parathyroid hormone (PTH) levels were 
significantly higher in the former than in the 
latter, whereas the other variables did not differ 
significantly (data are showed as mean + sem). 
25(OH)D, 25(OH) Vitamin D; 1,25(OH)D, 1,25(OH) 
Vitamin D.  
Adapted from Maniero C et al. J Hypertens 
2012;30:390-395.. 
Introduction 
 
 
 
Figure 5. Schematic representation of the possible bifunctional link between the adrenocortical zona 
glomerulosa and the parathyroid gland. Given the secretagogue effect of PTH on aldosterone, excess 
secretion of PTH can cause hyperaldosteronism, which in turn can modulate the secretion of PTH. 
Excess levels of PTH and aldosterone can have a detrimental effect on the vascular wall, resulting in 
vascular damage.  
From Rossi GP  et al. Hyperparathyroidism With current Primary Aldosteronism. Hypertension 
2011;58:341-346. 
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3.2 The Role of Aldosterone in Primary Hyperparathyroidism 
  
 Primary hyperparathyroidism (PHPT), the third most common endocrine 
disorder, is characterized by excess PTH secretion, which is inappropriate with respect to 
the prevailing concentration of ionized calcium or to increased secretory cell number 
(66).  In the long term, PHPT is associated with the development of osteoporosis and 
fracture risk, and higher risk of hypertension, left ventricular hypertrophy, arrhythmia, 
diabetes, hyperlipidemia, and, most importantly, cardiovascular morbidity and mortality 
(67-70).  
Evidence for a bidirectional link between aldosterone and PTH in humans had initially 
been derived mainly from case reports.  The first report was a patient with primary 
hyperparathyroidism and findings consistent with primary hyperaldosteronism: Elevated 
levels of plasma aldosterone, which could not be suppressed by a high sodium diet alone 
or in combination with fludrocortisone, a decline of the elevated plasma aldosterone 
levels after 4 h of deambulation and low PRA, which was unresponsive to stimulation by 
a low sodium diet coupled with diuretic-induced volume depletion and 4 h of 
deambulation. Removal of a parathyroid adenoma not only normalized Ca2+ and PTH, 
but also improved blood pressure, hypokaliemia, and aldosterone levels.  Since then, the 
role of PTH on aldosterone metabolism has remained controversial (71). 
In this context, our group also described a case report with a combination of 
unrecognized PA and resistant hypertension in an adult patient with evidence of 
hypertension-related target organ damage and a history of cardiovascular events.  The 
correction of PA with adrenalectomy and the development of hyperparathyroidism 
suggested the occurrence of a functional link between the adrenocortical zona 
glomerulosa  and the parathyroid gland, which was totally unsuspected.  The patient’s 
blood pressure first responded dramatically to adrenalectomy and then responded 
further to parathyroidectomy (26).  
Several cross-sectional and prospective studies also documented a strong relationship 
between aldosterone levels and arterial hypertension as well as increased arterial 
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stiffness.  In view of the interaction between aldosterone and PTH, one might speculate 
that the interplay between both hormones aggravates blood pressure elevation, blood 
vessels remodeling and cardiovascular disease in patients with elevated PTH (72,73).  
The interplay between PTH and aldosterone is increasingly suggested as an important 
mechanism underlying the increased risk of cardiovascular damage observed in PHPT.  
To explain the biochemical changes following parathyroid surgery, it has been suggested 
that hyperaldosteronism might be caused (directly or indirectly) by PHPT and vice versa 
(74-76). 
In summary, the observations that in patients with PHPT: (1) plasma aldosterone and 
PTH concentrations were positively correlated; (2) at multivariate analysis, preoperative 
PTH was an independent predictor of plasma aldosterone concentration; (3) PTH levels 
>100 ng/L were an independent predictor of abnormally elevated plasma aldosterone 
concentration, are consistent with the concept that PTH plays a role in triggering or 
maintaining aldosterone  secretion in vivo (77,65).  
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4. CELLULAR MECHANISMS UNDERLYING THE LINK BETWEEN 
ALDOSTERONE AND PTH  
Several experimental studies were performed with the aim of clarifying the 
mechanisms underlying the effect of PTH on aldosterone secretion from the adrenals.  It 
is well known that PTH stimulates the entry of cytosolic Ca2+ into the mitochondrial 
matrix and this step is essential for the initiation of steroidogenesis within the 
mitochondria (78-80).  However, it is still under investigation whether PTH stimulates 
adrenal aldosterone synthesis directly. 
Olgaard et al. evaluated the effect of PTH on Ca2+mediated aldosterone secretion in 
isolated rat adrenocortical zona glomerulosa  (ZG) cells.  Aldosterone release increased 
significantly by up to 200% above baseline values in cells exposed to PTH (1–84) and PTH 
(1–34), thereby suggesting that PTH exerts Ca2+ ionophore-like effects in the ZG causing 
increased Ca2+ stimulated aldosterone secretion (81). 
Mazzocchi et al. demonstrated that in dispersed adrenocortical cells PTH and PTH-
related protein increase aldosterone production by binding to the PTH/PTH-rP receptor, 
activating cellular adenylate cyclase/cAMPdependent protein kinase, phospholipase 
C/protein kinase C- and cAMP-dependent signaling cascades (82). In this context 
Maniero et al. found that both APA and nodules detected in adrenal hyperplasia 
expressed the type 1 PTH receptor at both the mRNA and the protein level.  A similar 
PTH receptor expression was found in other cases of PA that did not show 
hyperparathyroidism but only a subtle elevation of PTH plasma levels.  These findings 
could explain why human dispersed adrenocortical cells responded with aldosterone 
and cortisol release to either PTH or the PTH-related peptide. 
Another important finding contributing to support the mechanistic link between adrenal 
gland and parathyroid glands is the expression of MR in parathyroid cells (Fig. 1) (26). In 
epithelial tissues, MR activation by cortisol is mainly prevented by the cortisol-
inactivating enzyme 11β-hydroxysteroid dehydrogenase-2. In the setting of increased 
generation of reactive oxygen species, e.g. in chronic kidney disease and heart failure, 
cortisol might also activate the MR—in addition to aldosterone—thus aggravating 
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profibrotic and proinflammatory effects (83, 84).  To date it is unclear, however, 
whether cortisol affects renal handling of Ca2+ via binding to the MR. One recent study 
revealed an upregulated expression of PTH-related peptide in the mice kidney after 4 
weeks treatment with cortisol.  Moreover, in a small cohort of patients with PHPT, 
circulating cortisol levels decreased significantly after parathyroidectomy (85, 86).  
Conversely, intravenous infusion of PTH in healthy adults increased plasma cortisol 
concentration (87).  Since 1) hypercalcaemia, caused by PTH excess, results in a transient 
rise of adrenocorticotropic hormone secretion; 2) PTH stimulates steroid hormone 
synthesis in part by binding to the adrenocorticotropic hormone receptor; 3) cortisol 
upregulates PTH-related peptide, one might speculate that this sequence may impact on 
cardiovascular health.  In this perspective the conceivable relationship between 
glucocorticoids and the steroid-related marker 11β-hydroxysteroid dehydrogenase-2 
with PTH remains to be addressed (62).  
 
 
 
 
 
 
 
 
 
  
 
Hypothesis-Primary Objective-Specific Aims 
 
 
HYPOTHESIS 
The recent detection of the MR in parathyroid cells (26) suggestthat PTH plays a role in 
mantaining overproduction of aldosterone in PA in spite of suppression of the renin-
angiotensin system, thereby suggesting a relationship between parathyroid glands and 
the adrenocortical zona glomerulosa.   
The investigation in this field of this relationship has been hampered thus far by the lack 
of a parathyroid cell line suitable for in vitro studies.Therefore, we planned to develop a 
technique to obtain a primary culture of human parathyroid cells with high yield and 
purity and to obtain subpopulations of chief and oxyphil cells. 
 
Primary Objective 
To develop a human parathyroid cell line that can be used for investigating the 
mechanisms underlying the effects of aldosterone on PTH synthesis and secretion. 
 
Specific Aims 
1. To develop a protocol to obtain a pure primary culture of human parathyroid 
cells. 
2. To develop a protocol to separate and collect two cell types, e.g. chief and 
oxyphil cells, that constitute the parathyroid tissue. 
3. To evaluate the gene and protein expression levels of the markers specific for 
parathyroid cells in the separated oxyphil and chief cells. 
4. To evaluate PTH synthesis and production in the primary cultures.
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MATERIAL AND METHODS 
Tissue Dispersion 
Tissue samples were obtained in the operating room from patients undergoing surgery 
for parathyroid adenoma. After removal of visible fat and capsule the glands were 
minced and then treated by digestion in 1 mg/ml collagenase type II , 0.05mg/ml  DNAse 
I (Roche; Milan Italy) in RPMI-1640 media (Sigma-Aldrich®,Italy) for 2 cycles of 20 
minutes at 37°C, followed by mechanical disaggregation (GentleMACS™ Dissociator by 
Miltenyi Biotec). Cells were filtered through a 40 mm cell strainer, and then centrifuged 
for 5 min at 800x g.  Their viability was assessed by trypan blue exclusion. 
Cell Isolation and Culture 
Cell suspension obtained after enzymatic and mechanic digestion was washed with 
RPMI-1640 medium (Sigma-Aldrich®, Italy) and then incubated with CD90 coated 
magnetic beads by gentle shaking for 30 min at 4 °C. Beads were used at a ratio of five 
beads per cell. After separating the bead-bound CD90 positive cells with a magnet, CD90 
negative cells were cultured at a density of ~1x105 cells into 75 cm3 tissue culture flask 
(Nunclon Delta Surface Thermo Scientific) or six well plate (Multiwell TM 6 well Becton 
Dickinson Labware) and maintained in a humidified 5% carbon dioxide/air atmosphere 
at 37 C. Fresh medium was added every 48 hours. 
Precoating of Magnetic Beads 
To eliminate fibroblast contamination, magnetic beads (Dynabeads; Invitrogen, Milan, 
Italy) (1x107/25μl) conjugated with goat anti-mouse IgG were washed three times with 
PBS/0.1% BSA and then precoated with 1.5 μg mouse monoclonal antibody against 
human CD90 (Thymus cell antigen 1, an anchored membrane protein express in 
fibroblast cell membrane). Pre-coating was obtained by incubating the beads with the 
primary mouse antibody overnight at 4 °C under rotation.  Beads were washed three 
times with PBS/0.1% BSA and then used for cell separation by depletion of fibroblast 
cells. 
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Separation of Parathyroid Cell by Size-Selective Isolation 
The isolation of cells was performed with Screencell Cell Culture Kit ® (Screencell 
Technology USA) with a protocol modified for tissue samples.  The ScreenCell® filtration 
devices were developed in order to isolate circulating tumour cells by size on a 
microporous membrane filter, where circular pores are calibrated 7.5±0.36 μm or 
6.5±0.33 μm and randomly distributed throughout the filter (88). 
a. Filtration. After tissue digestion, cells were suspended in RPMI media with antibiotic 
(4-6 ml depending of the sample size), and then added 1 ml of ScreenCell LC dilution 
buffer  for 2 minutes in order to lyse red blood cells: The reaction was stopped by adding 
1.6 ml culture medium. The sample filtration was performed according to the producer’s 
instruction. 
 b. Cell Culture. The filter with cells was cultured in a 24-well tissue culture plate 
(Multiwell TM 24 well Becton Dickinson Labware) with  RPMI-1640 medium 5% FBS  while 
the supernatant, or filter cells, was obtained by centrifugation 5 minutes at 4,2 min-1 or 
by dilution in small volume of culture media.  All cell types were used within 10 day of 
culture for all experiments (Fig.6). 
Electron Microscope  
For electron microscopy studies, oxyphil and chief parathyroid cells were separated with 
ScreenCell®Cyto filters and then cultured in 24-multi-well insert systems treated with 
Matrigel®   (BDBiosciences, Australia). Classic primary culture were maintained in 
standard 24-well tissue culture plate (Multiwell TM 24 well Becton Dickinson Labware)  
for 5-12 days.  
Monolayers of parathyroid cells were fixed in 3% in glutaraldehyde (Serva 
Electrophoresis- Heidelberg, Germany) in 0.1M phosphate buffer, post-fixed in 1% 
osmium tetroxide (Agar Scientific Elektron Technology,UK ) in 0.1M phosphate buffer, 
dehydrated and then embedded in an Epoxy Embedding Medium Kit (45349 Sigma-
Aldrich, Switzerland). Ultrathin sections (60-nm) were cut with an ultramicrotome, (LKB-
8800 Ultratome III Stockholm, Sweden) collected on 400-mesh copper grids, 
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counterstained with 2% uranyl acetate and then with Sato’s lead. Specimens were 
observed by a Hitachi H-300 Transmission Electron Microscope. 
 
Figure 6. Schematic representation of culture process. Tissue samples from patients with parathyroid 
adenoma were minced after capsule removal (Step 1), then treated by digestion solution and mechanical 
disaggregation (Step 2). After digestion the cells were dispersed  and cultured  to obtain a “Classic Primary 
Culture” where  oxyphil and chief  cell  grow  together (Step 2A).Cell suspension was filtrated  to obtain  
separated oxyphil and chief cells (Step 3A).The big cells or oxyphil cells remain on the filter and grow on it, 
whereas the small cells or chief cells  went through the filter and were culture on glass slide. 
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Phenotypic Characterization of Cells 
To determine whether the isolated cells showed a parathyroid phenotype, we 
performed real time real time qRT-PCR experiments to measure the gene transcripts 
Calcium sensing receptor (CaSR), Parathyroid Hormone (PTH), Glial cell missing-2 
homolog (GCM2, a specific transcription factor that has been shown to be essential for 
development  of parathyroid gland  and is expressed in mature parathyroid) (89-91), 
Mineralocorticoid Receptor (MR), Glucocorticoid Receptor (GR) and 11β-hydroxysteroid 
dehydrogenase type 2 (11βHSD2). 
Total RNA was extracted from cells using the RNAqueous microkit (Ambion®Life 
Technologies; Monza, Italy); its integrity and quality was systematically checked with a 
laboratory-on-chip technology in an Agilent Bioanalyzer 2100 with the RNA6000 Nano 
assay (Agilent Technologies; Milan, Italy). 1 μg of total RNA were reverse transcribed 
with Iscript (BioRad; Milan, Italy) in a final volume of 20 μl. The mRNA was measured 
with a real time qRT-PCR with universal ProbeLibrary probes in the LightCycler 480 
Instrument (Roche; Milan Italy). The expression was calculated relative to actin used as 
an internal control. 
Immunohistochemistry  
For immunocytochemical analysis, oxyphil cells were stained directly on the circular 
filter (ScreenCell® Cyto) and chief cells on the slide glass. Separated cells were fixed for 
10 min with 2% paraformaldehyde in phosphate-buffered saline (PBS) at pH 7.4, and 
then washed in PBS. Endogen peroxidases were blocked with 0,5% H2O2 in PBS for 10 
min at room temperature. Samples exposed to anti-rabbit or anti-mouse secondary 
antibodies were pre-incubated with a permeabilizing buffer (0.2% Tween-20 in PBS) for 
60 min at room temperature; samples exposed to anti-sheep antibody (11βHSD2- 11β 
hydroxysteroid dehydrogenase) were incubated with 0.5% Tween 20 in  Super Blocker 
(ThermoScientific-Rockford ,USA) for 60 min at room temperature. 
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Separated parathyroid cells were incubated with a monoclonal antibodies at a dilution 
1:500 for anti-PTH antibody (GTX39458; GeneTex, Inc. CA. USA), 1:70 for anti-CaSR 
(ab19347; Abcam Cambridge,UK),  1:50  for anti-Mineralocorticoid Receptor (a kind gift 
of Dr. Celso Gomez-Sanchez  Dept. of Medicine, University of Mississippi Medical Center, 
Jackson, MS).   
Rabbit polyclonal antibodies were diluted 1:300 for anti-Chromogranin A (ab15160 -
Abcam- Cambridge,UK), 1:80 for anti-Gcm2 (ab96063 Abcam Cambridge,UK); sheep 
polyclonal antibody 11βHSD2 (a kind gift of Prof. Paul Stewart Dean of School of 
Medicine, University of Leeds, Leeds,UK) was diluted 1:200. All primary antibodies were 
diluted in the same pre-incubation buffer and incubated overnight at 4°C.                           
After repeated PBS washing, samples were incubated with a secondary antibody and 
Advance HRP Detection System Kit (Dako Corp. Carpinteria, CA, USA) for mouse and 
rabbit antibodies, and with secondary antisheep HRP (P0163 Dako Corp, Carpinteria CA, 
USA) for 11βHSD2 antibody 1:100 for 60 min at room temperature. The immune 
complexes were visualized with 3,3’-diaminobenzidine (Dako Corp, Carpinteria, CA, 
USA).  Distilled water was used to stop the reaction. 
The circular filter and glass coverslip was then dried at room temperature and mounted 
on a glass slide.  Negative controls were carried out by similarly treating sections and 
omitting the primary antibody.  The images were acquired by Leica DMR microscope. 
11βHSD2 Protein Expression 
Protein expression was quantified by immuno-blot analysis. To this aim APA samples 
(n=3), normal adrenal gland (n=3), parathyroid gland (n=3), kidney tissue (n=4), A549 
cells (Homo sapiens lung carcinoma cells) and HepG2 cells (Human Hepatocyte 
Carcinoma) were homogenized in 600μl lysis buffer (Thermo Scientific, Italy) using a 
MagNALyser Instrument (Roche, Italy).  Protein concentration was determined in the 
soluble supernatant with BCA (Thermo Scientific, Italy). Lysate fraction (50 μg) was 
separated from acrylamide gel and then was electro blotted onto nitrocellulose 
membrane (Hybond ECL-Amersham Biosciences Europe, Germany).The membranes were 
blocked for 1h at room temperature in 0,5% Tween 20 in  Super Blocker 
(ThermoScientific-Rockford ,USA) and thereafter incubated overnight at 4°C with a 
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primary sheep polyclonal antibody against type 2  11βHSD2 (1:100 dilution) (a kind gift 
of Prof. Paul Stewart Dean of School of Medicine, University of Leeds, Leeds,UK) .Blots 
were analyzed by the QuantityOne Program of VersaDOC 1000 (Bio-Rad, Italy). 
PTH Measurement 
To determine the functionality of parathyroid primary cells we stimulated them with 
three different concentrations of calcium: 0.5, 1.5 and 3.0 nM for one hour in medium 
without calcium and low serum concentration (Fetal Bovine Serum 0.5%). 
Detectable amounts of calcium were detected with an Elisa Assay for  Human Bioactive 
PTH 1- 84 (Immutopics, Inc. CA USA
variability of cells the number among cultures (92). 
Mitochondrial Membrane Potential 
This was measured based on the accumulation of tetramethylrhodamine methyl ester 
(TMRM). Cells were seeded onto 24-mm-diameter round glass coverslips and grown for 
2-11 days in RPMI-1640 medium 5% FBS (Sigma-Aldrich®,Italy).The extent of cell and, 
hence, mitochondrial loading with potentiometric probes is affected by the activity of 
the plasma membrane multidrug resistance pump, which is inhibited by Cyclosporin (Cs) 
A. Treatment with this drug may therefore cause an increased mitochondrial 
fluorescence that can be erroneously interpreted as an increase of the mitochondrial 
membrane potential (93). To prevent this artifact and to normalize the loading 
conditions, in all experiments with TMRM the medium was supplemented with 1.6 μM 
CsH, which inhibits the multidrug resistance pump but not the permeability transition 
pore (PTP) (94). Cells were rinsed once and then incubated in bicarbonate- and phenol 
red-free Hank’s balanced salt solution (Sigma-Aldrich®, Italy) supplemented with 10mM 
Hepes and 1.6 μM CsH and loaded with 10 nM TMRM for 30 min. At the end of each 
experiment, mitochondria were fully depolarized by the addition of 4 μM of the 
protonophore carbonyl cyanide p-trifluoromethoxyphenylhydrazone (FCCP). Cellular 
fluorescence images were acquired with an Olympus (Center Valley, PA) IX71/IX51 
inverted microscope equipped with a xenon light source (75 W) for epifluorescence 
illumination and with a 12-bit digital cooled charge-coupled device (CCD) camera 
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(Micromax, Princeton Instruments, Trenton, NJ). For detection of fluorescence, 568 ± 25-
nm bandpass excitation and 585-nm longpass emission filter settings were used. Images 
were collected with an exposure time of 100 msec by using a ×40, 1.3 N.A. oil immersion 
objective (Nikon). Data were acquired and analyzed by using CellR software (Olympus). 
Clusters of several mitochondria (10–30 clusters) were identified as regions of interest, 
and fields not containing cells were taken as the background. Sequential digital images 
were acquired every 2 min, and the average fluorescence intensity of all relevant regions 
was recorded and stored for subsequent analysis.  
Statistical Analysis 
Results were expressed as mean ± SE of at least 3 separate experiments in which each 
samples was assayed in duplicated. Differences between groups were analyzed by t-test 
and, for multiple group comparison, by one-way ANOVA. The differences were 
considered to be significant at p < 0.05. Statistical analyses were performed using 
Graphpad/prism 5 for Windows software (Graphpad Software, La Jolla, California, USA; 
www.graphpad.com).
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RESULTS 
Primary Cell Culture from Parathyroid Adenoma  
As described in detail in Material and Methods section, cells isolated from 
parathyroid adenomas were cultured to obtain a classic primary culture where chief and 
oxyphil cells were grown together. The next step was to separate chief from oxyphil cells 
and separately grow them in order to obtain two different primary cultures. 
All seeded cells were adherent to the bottom of well-plate after 24 hours. In general, 
more than 95% dispersed cells were viable and grew in columnar aggregates, small 
clusters or in pseudofollicle formation. We observed that such cell clusters consisted of 
round cells with different sizes with well defined borders and that they represented the 
majority of the cultured cells(Fig.7 panel A and B).. Occasionally spindle-shaped cells 
grown far from the clusters, presumably fibroblasts, were found in the culture (Fig.6 
panel A). The fibroblast contamination was avoided by immunobinding technique using 
an antibody against  fibroblast  membrane marker (CD90) (95).This technique was 
successfully used in the past by our group with the aim of obtaining a pure population of 
adrenal cells (96). 
Classic primary cultures were passaged once (when the confluence exceed 90% of 6 well 
plates) but in general the culture was continuous (without passages) because this type 
of cells need  cell-to-cell contacts to survive along the culture (97). Cultures of chief and 
oxyphil cells were maintained only as continuous culture due to small number of chief 
cells and the frailty of the oxyphil cells. Since the oxyphil cells showed a poor survival 
when detached from filters, the cells were cultured on the filters thereby avoiding any 
cell damage. 
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Ultrastructure of Parathyroid Adenoma Cells  
 Cells derived from classic primary cultures were maintained on the plate where 
they were growing (~5-10x105 cells/24 well plates) for the analysis at TEM. Two cell 
types, different for the amount of mitochondria, were easily distinguishable: one type, 
presumably oxyphil cells, was very rich in mitochondria that engulfed the cytoplasm, 
whereas the other cell type, presumably the chief cells, contained mitochondria usually 
localized only in one portion of the cell.  Both cell types were joined by tight junctions 
thereby forming a continuous layer. Both oxyphil and chief cells contained many 
vacuoles, glycogen deposits and lipid droplets in the cytoplasm (Fig. 8). Occasionally 
nuclear pleomorphism was detected. 
B
CG
Cl
Cl
Ps
Figure 7. A. Growth cell in classic primary cell culture with occasional spindle-shaped cells (*) Original 
magnification x10 B. Columnar cell group (CG), Clusters (Cl)  or Pseudofollicle formation (Ps). 
Toluidine Blue staining. Original magnification x20.  
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When the cells were isolated using a filter size-based technique, oxhyphil and chief cells 
were separately cultured and then analyzed in 24-multiwell insert system (~5x104 
cells/24 well plates). Oxyphil cells showed more abundant mitochondria than the chief 
cells, thereby confirming that the cells rich in mitochondria that we observed in the 
primary cultures were actually oxyphil cells. Golgi apparatus and endoplasmic reticulum, 
rough and smooth, were less prominent in both cell types. As observed in the classic 
primary cultures, both cell types showed secretory granules and large amounts of 
glycogen (Fig.9). 
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Figure 8. Ultrastructure of parathyroid adenoma cells A. Presence of tight junctions (black arrows) 
original magnification x 10000. B. Glycogen deposits (*) original magnification x 7000. C and D. 
Mitochondria content: HC Cells with abundant mitochondria, LC Cells with few mitochondria, original 
magnification x 7000. (C) Cell (N) Nucleus (M) Mitochondria (V) Lipid droplet.  
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Figure 9. Ultrastructure of parathyroid adenoma cells A. Oxyphil cell with bigger amount of 
mitochondria and glycogen deposits (*) Original magnification x 5000 B. Adjacent oxyphil cells 
with abundance of mitochondria . Cellular junctions between them are clearly evident (black 
arrows). Original magnification x 10000. C. Chief cells with smaller content of mitochondria and 
glycogen deposits Original magnification x 4000 D. Chief cell. at greater magnification, x 15000 
(N) Nucleus (M) Mitochondria. 
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Parathyroid Cell Markers: Gene and Protein Expression 
 Real-time qRT-PCR showed the expression of parathyroid markers including 
CaSR, GCM2 and PTH, and the steroids-related markers MR, GR, and 11βHSD2 in the 
primary classic cultures.  No significant differences between primary cell cultures and 
tissue parathyroid samples collected from same patients with an adenoma at day 5 of 
culture were found.  Likely this was because of the spread values and therefore to the 
intrinsic cell variability between adenomas (Fig. 10 panel A). 
By contrast, the gene expression of most parathyroid cell markers, i.e. CaSR, MR, 
11βHSD2 and the transcription factor GCM2, significantly decreased after  day 10 as 
compared to the adenoma tissue (Fig. 10 panel B). A reduction in CaSR expression has 
been previously described in parathyroid adenomas and hyperplastic parathyroid tissues 
(10-13), but no information was available for the other markers. 
The expression of PTH found in the classic primary culture with real time qRT-PCR was 
confirmed by immunocytochemistry.  The specific immuno-signal for PTH was in fact 
observed in at least 90% cells, albeit, with differences between cellular types. As 
previously reported in the literature, PTH was more expressed in the chief than in the 
oxyphil cells (2). Such difference was found in both classic primary cultures and 
'separate' cultures of cell types (observational data) (Fig.11 panel A and Fig.12).  
A similar protein expression pattern was found for CaSR and CGA as shown in Fig.11, 
panels B and C.  In contrast, no difference between cell types could be appreciated for 
the parathyroid specific transcription factor GCM2, which has been held an essential 
factor for parathyroid development  and therefore relevant for both cell types (15) 
(Fig.11 panel D and Fig.12 panels C and D ). 
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When investigating the steroids-related markers, we found that both classic primary 
cultures and 'separate' cultured cells express MR and 11βHSD2 proteins (Fig. 13 panels A 
and B). MR was found to be expressed in the cytoplasm but not in the nucleus in the 
oxyphil cells, whereas it was expressed in both compartments in the chief cells (Fig. 13 
panels C and D). The specificity of the immune-signals was confirmed by the negative 
controls for each reaction.  
The expression of 11βHSD2 in the parathyroid was confirmed by immunoblot 
experiments.  Of interest, the levels of 11βHSD2 protein in the parathyroid tissue were 
similar to those of adrenal gland or APA, which express at 11βHSD2 to high extent.  The 
levels found in the parathyroid tissue were smaller, even though not significantly, than 
those found in the kidney, the organ with the highest 11βHSD2 synthesis ( Fig. 14 ). 
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Figure 10.Parathyroid  and steroids-related markers gene expression. A. The expression of 
most cellular markers in classic primary cell cultures at day 5 does not show significant 
difference as compared to parathyroid adenoma tissue. Only Expression of CaSR 
significantly decreased (p<0.05) B. Classic primary cell cultures  at day 10 showed a 
significant decrease in CaSR,GCM2 and MR gene expression (n=7) 
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Figure 11. Immunocytochemestry of parathyroid cell markers in classic culture. A. PTH, 
Original magnification x 63 B.Chromogranin A, Original magnification x 40 C. CaSR, Original 
magnification x 40 D. GCM2 staining, Original magnification x 63 (NC) Negative control.  
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Figure 12. Immunocytochemistry of separated cells. A. PTH staining in oxyphil cells, original 
magnification x 63 B. PTH staining in chief cells, original magnification x 40 C. GCM2 staining in 
oxyphil cells, original magnification x 63 D. GCM2  staining in chief cells, original magnification x 
63. (NC) Negative control.   
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Figure 13. Immunocytochemistry of primary cultured cells. A. MR staining in classic 
primary cultures, original magnification  x 63  B. 11βHSD2 staining in classic primary 
cultures, original magnification  x 40  C. MR staining in oxyphil cells, original magnification  
x 40 D. MR  staining in some chief cells  E. 11βHSD2 staining in oxyphil cells, original 
magnification  x 63  F. 11βHSD2 staining in chief cells, original magnification  x 63.(NC) 
Negative control.   
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Figure 14. 11βHSD2 expression in different tissues. Protein expression in parathyroid 
(lane 2),normal adrenall tissue (lane 3)  and aldosterone producing adenoma (APA)  
(lane 4) was found to be similar to that of kidney tissue (lane 1). A549 and HepG2 cell 
lines  (lanes 5 and 6)were used as negative controls and GAPDH  used as internal 
control. 
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PTH Production 
The ability of the parathyroid cells to produce PTH in the classic primary cultures was 
investigated at days 5 and 10 of culture by adding Ca2+ at three different concentrations.  
In presence of low Ca2+ levels (0.5 mM)  for 1 hour the production of PTH was 
significantly increased at days 5 and 10 (p=0.028 and p=0.018, respectively) as compared 
to the control.  No significant effect was observed after 1.25nM and 3nM Ca2+ addition 
at the same times (p=0.68 and p=0.62 , p=0.96 and p=0.063 respectively) (fig. 15 ). 
Mitochondrial Membrane Potential  
In normal aerobic conditions the combination of proton pumping by the respiratory 
chain and of low permeability of the inner mitochondrial membrane (IMM) to charged 
species allows the build up of a high proton motive force that drives ADP and Pi uptake, 
and synthesis of ATP by the F1F0ATP synthase (98).  The proton motive force has two 
components: one due to the concentration difference of protons across the membrane 
(ΔpH) and one ,the membrane potential (ΔΨ) due to the difference in electrical 
potential between the two aqueous phases separated by membrane.  ΔpH in mammals 
cells is about 0.5-1 units, which correspond to 30-60 mV and ΔΨ  is in the order of 140-
170 mV (inside negative). The earliest consequence of depolarization (e.g. following 
impaired respiration) is a switch of the mitochondrial F1F0ATP synthase from its 
physiological mode of operation to that of an ATP hydrolase, when the glycolytic ATP is 
available. 
Since we found in the TEM experiments that oxyphil cells have higher mitochondrial 
content than chief cells, we tested whether this can reflects a functional difference in 
parathyroid primary cells. We therefore monitored the mitochondrial ΔΨ (ΔΨm) in 
oxyphil and chief cells in situ by measuring their accumulation of tetramethylrhodamine 
methyl ester (TMRM). Cells where treated with CsH, which inhibits the multidrug 
resistance pump and therefore normalizes cytosolic loading with TMRM, which is a 
substrate of the pump and could therefore be extruded at rates that vary widely in 
different cell types. Mitochondria readily accumulated TMRM, indicating that they are 
energized, and they showed (Fig. 16 panel A) a heterogeneous staining pattern  with a 
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higher fluorescence in oxyphil cells. Addition of the F1FOATP synthase inhibitor 
oligomycin to the cultures from  human adenoma parathyroid cells was followed by 
increased probe uptake (i.e., by the expected hyperpolarization), followed by a process 
of TMRM release that appeared to have an earlier onset in oxyphil cells (Fig. 16 panel B). 
In both cell types fast TMRM release followed addition of the protonophore carbonyl 
cyanide p-trifluoromethoxyphenylhydrazone (FCCP).  
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Figure 15. Effect of Ca2+ on  classic primary cultures at  day 5 (A) and   day 10 (B). 
Significant increase of PTH was found at low calcium concentration (0.5nM) vs. control 
(no Ca2+ addition). 
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Figure 16.Changes in mitochondrial TMRM fluorescence induced by oligomycin in primary 
cell cultures from parathyroid glands. Cell culture established from biopsy was loaded with 
TMRM and studied as described in "Matherial and methods". A. Representative examples 
of cells loaded with TMRM before oligomycin addition; oxyphil cells are marked in blue and 
chief cells in green. B. Where indicated by arrows 6 μM oligomycin (Oligo) and 4 μM FCCP 
(F) were added. Each trace reports the response of one individual cell. 
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The aim of the present study was to develop a human parathyroid cell line that 
could be used for investigating the effects of aldosterone on PTH synthesis and 
secretion.  The detection of the MR in parathyroid cells, alongside recent evidences 
implicating PTH in overproduction of aldosterone in primary aldosteronism in spite of 
suppression of the renin-angiotensin system, suggests a relationship between 
parathyroid and the adrenocortical zona glomerulosa.  However, the investigation of 
such relationship has been hampered because of lacking of parathyroid cell line suitable 
for in vitro studies.  Moreover, cultures previously developed in other laboratories do 
not allow distinction between cell types (99). Here, we describe a novel technique to 
isolate the two main parathyroid cell subtypes e.g. chief and oxyphil cells. 
Primary Cell Culture from Parathyroid Adenoma 
Our initial approach was to develop a protocol to obtain a pure primary culture of 
human parathyroid cells. After several experiments we found that the most 
advantageous conditions include: (1) automated tissue dissociation to obtain a single-
cell suspension, (2) immunobinding-based technique to remove fibroblasts, (3) high 
cellular confluence (~3-5x105 cells/well) on culture well to stimulate a tissue- like 
architecture, (4) cell culture medium with moderate serum concentration (5% of total 
medium volume) and (5) continuous culturing without subculture.  
We also found that the protocols that were previously developed in other laboratories 
did not allow maintenance of functionally active parathyroid cells for long times, most of 
them being characterized by a rapid and significant loss of PTH secretion within 3-4 days 
(99-101). 
In contrast, using the above described approach we were able to obtain an appreciable 
PTH production until day 10 of culture. At this time our cultured cells lost CaSR 
expression.  The significance of CaSR expression loss after some days of culture, albeit 
described by other investigators, is not clear.  Reduced  CaSR mRNA and protein levels 
were found in cultured bovine parathyroid cells placed in primary monolayer culture, 
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and this change was associated with reduced responsiveness to Ca2+(102-108).  In 
contrast, our cells maintained PTH production even after 5 days of culture, likely 
because the cellular growth occurred in a tissue-like architecture manner.  Actually, the 
short time exposure to collagenase type II (maximum 20 minutes) and the automated 
dissociation provided a single-cell suspension with no cell damage.  Hence, integrity of 
cell membranes allowed the development of a tissue-like structure, with pseudofollicles 
at high cellular confluence (~5x105 cells/well), which involves reconstruction of 
extracellular matrix in the plate well.  Cultured cells mimicked the original parathyroid 
structure in the continuous culture, at least for a short period (~10 days).  
The contention that organ-like structure is of utmost relevance is supported by data by 
Ridgeway et al.and Ritter et al. who, some years ago, found that bovine and human 
parathyroid cells cultured as multicellular aggregates named Organoids maintained their 
morphology and function, including their response to Ca2+ for at least 2 weeks in vitro. 
Ritter et al. also were able to reproduce pseudogland in continuous cultures by using 
collagen support (97,105,109).We tried to exploit the previously described protocols, 
but unfortunately we could not obtain good results, likely because our tissue samples 
were very small.  
Parathyroid Cell Morphology, Markers Expression and Function. 
Both intercellular contacts between cells from the same cluster and parathyroid tissue-
like architecture play an important role in the maintenance of differentiated cellular 
function in cultured parathyroid cells. Our primary cells  formed clusters up to 10 days 
(Fig.7), thereby showing cell integrity and ability to resemble the original tissue 
structure.  
By exploiting a novel procedure, we also successfully separated chief from oxyphil cells. 
The cells were viable expressed specific markers of parathyroid glands, and, more 
importantly, they were functionally active because were able to produce PTH at least for 
10 days, as classic primary cell culture, and  expressed CaSR, PTH,GCM2 and CGA. Of 
interest we first identified steroid-related markers such as MR, GR, and 11βHSD2 in 
parathyroid cells. Expression of 11βHSD2 in the parathyroid tissue confirmed that 
steroid-related markers are specific of this tissue.  These findings provide experimental 
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support to the hypothesis that hyperaldosteronism may be caused by primary 
hyperparathyroidism and vice versa.  Further studies are required to better clarify this 
relationship. 
By analyzing fixed tissue samples, two studies reported that key genes of parathyroid 
function are expressed in both oxyphil and chief cells of hyperplastic parathyroid glands 
from patients with secondary hyperparathyroidism (2).  This finding was in contrast to 
the old argument that oxyphil cells are 'deactivated' chief cells not expressing 
parathyroid markers.  By showing that both cell types express parathyroid markers, as 
well a different amount in mitochondria content;a hallmark of parathyroid cell subtypes 
(110),our study confirm the hypothesis that both oxyphil and chief cells are 
'differentiated' parathyroid cells (Fig. 8 and Fig.9). 
Mitochondrial Membrane Potential 
We found by TEM that in parathyroid primary cells cultures oxyphil cells have a 
higher mitochondrial content respect to chief cell, conserving the pattern already 
reported in the human parathyroid gland (2). Studying the mitochondrial function by 
measuring ΔΨm we observed a heterogeneous pattern in the signal intensity in oxyphil 
and chief cells (Fig. 16 panel A). Addition of the F1F0ATP synthase inhibitor oligomycin 
caused hyperpolarization, as expected of phosphorylating cells. Indeed, in respiring cells 
the ΔΨm is maintained by proton pumping through the respiratory chain, and ATP 
synthesis draws a fraction of the proton gradient, which therefore increases when the 
ATP synthase is blocked.  The initial hyperpolarization induced by oligomycin was 
followed by depolarization in a process whose onset appears to be much earlier in the 
oxyphil cells.  This anomalous response to oligomycin (i.e., depolarization) was also 
detected in some myopathies, including Ullrich congenital muscular dystrophy (UCMD) 
and Duchenne muscular dystrophy (DMD) (111,112), where it was attributed to opening 
of the permeability transition pore (PTP, a high conductance inner membrane channel) 
following addition of oligomycin.  Future studies with CsA, a cyclophilin inhibitor that 
desensitizes the PTP, will address the question of whether in cells from parathyroid 
primary human adenoma inappropriate opening of the PTP is also involved in the 
oligomycin-induced mitochondrial dysfunction observed in these preliminary 
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experiments; and whether the earlier onset seen in oxyphil cells has a 
pathophysiological relevance.  Oxyphil cells are increased in the parathyroid glands of 
CKD patients, and they have been reported to serve a different, albeit undefined, 
function  relative to  chief cells (2,113): additional studies are required to clarify the role 
of these cells in parathyroid pathophysiology. 
Limitations of the Study 
We would like to point out that this study has some limitations.  One limitation is that 
we have not yet investigated PTH synthesis in separated cells.  This was because of small 
number of chief cells observed after filtration and poor survival rate of oxyphil cells after 
detachment from the filter.  
Another limitation is the relatively short time of our cultures. Since the parathyroid cells 
cease to proliferate within few days in culture (108), longer times were not feasible.  A 
further limitation is the small sample size  Therefore supplementary studies are required 
to clarify the role of cellular subtypes in parathyroid and their possible influence in 
another target tissues, e.g. adrenal gland. 
Clinical Relevance 
The findings of our study showing a link between hyperaldosteronism and PTH 
oversecretion that could have clinical implications not only for primary aldosteronism 
patients, but also for patients with hyperaldosteronism secondary to the  activation of 
the renin–angiotensin system, as those with heart failure, renovascular hypertension. 
The ocurrence of steroids-related markers found in parathyroid tissue and culture 
parathyroid cells, as well as the observation that removal of a PTH secreting adenoma 
was followed by a decrease in  blood pressure values (26) support our contention. 
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Perspectives 
The observation that oxyphil, but not chief cells, are increased in hyperparathyroidism 
suggest that the two cell types may play a different secretory and sensing activities. 
Further studies would be necessary to clarify if the oxhyphil and chief cells may activate 
different signalling pathways in response to secretagogues, e.g. Ca2+ or feasibly 
steroids, and moreover if they undergo apoptosis or hyperplasia when are abnormally 
stimulated with excess of PTH and/or aldosterone.
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